PRIMO 2023 | The role of PSMA PET in recurrent prostate cancer

Ravi Madan, MD, National Cancer Institute, Bethesda, MD, discusses the utility and benefits of PSMA PET in diagnosing recurrent prostate cancer. Patients with recurrent prostate cancer, or metastatic castration-sensitive prostate cancer, often have limited treatment options, and may not benefit from treatments assessed in various trials such as STAMPEDE (NCT00268476), LATITUDE (NCT01715285), and CHAARTED (NCT00309985). A clinical trial is additionally underway that will monitor the progress of patients who are only identifiable via PSMA PET scans. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.